Wissam Baghdadi is Sangamo’s Engineer in Process Development, and in this role he develops manufacturing processes for Sangamo’s cell therapies using gene edited regulatory T cells, or Tregs. He is notably in charge of optimizing cell purity, quality, and quantity. Wissam notably played a key role in developing Sangamo’s proprietary CAR-Treg manufacturing process used in the first-in-human STEADFAST clinical study. He is also closely involved in the transfer of Sangamo’s processes to manufacturing teams, both internally and externally.
Wissam has been with Sangamo Therapeutics France – formerly known as TxCell prior to its acquisition by Sangamo in 2018 – since 2014.